González-Hernández MM, Montero-Vela J, Lizárraga-Verdugo ER

Language: Spanish
References: 13
Page: 17-24
PDF size: 186.79 Kb.

ABSTRACT

Objective: To measure and compare the macular thickness before and after treatment with spironolactone in the treatment of acute central serous chorioretinopathy.
Methodology: A comparative, observational, retrospective, longitudinal cohort study was conducted, analyzing patient records from June 2023 to May 2024. Patients diagnosed with central serous chorioretinopathy treated with oral spironolactone were included, and a comparison was made between anatomical variables before and after treatment.
Results: The macular thickness measurement before treatment was 394.5 µm (124.0 µm) and post-treatment was 319.0 µm (133.5 µm), with a difference of 75.5 µm, which was statistically significant (p ‹ 0.001). Subretinal fluid before treatment had a median of 161.5 µm (86.2 µm), and post-treatment was 119.5 µm (164.7 µm), with a difference of 42.5 µm. Best-corrected visual acuity (BCVA) had a median of 0.4 (0.5) before treatment and 0.2 (0.4) after treatment.
Conclusion: A reduction in macular thickness after treatment with oral spironolactone (25 mg every 24 hours), as well as a decrease in subretinal fluid and an improvement in best-corrected visual acuity.

REFERENCES

1. Palacios DLL, Fernández JCN, Ospina JPD,Castro LMU. Caracterización de la coriorretinopatíaserosa central en pacientes atendidosen el 2019 en el área de oftalmologíahospital IESS Portoviejo. Dom Cien 2022;8(1):787–801.

2. Long H, Liu M, Hu Q, Li X. 577 nm subthresholdmicropulse laser treatment for acutecentral serous chorioretinopathy: a comparativestudy. BMC Ophthalmol2022;22(1):105-111.

3. Mohanty A, Mahapatra SK. Funduscopy-guidedfluorescein angiography-free focal laserphotocoagulation for central serous chorioretinopathy.Indian J Ophthalmol2022;70(3):890–4.

4. Van Rijssen TJ, Van Dijk EHC, Tsonaka R,Feenstra HMA, Dijkman G, Peters PJH, et al.Half-dose photodynamic therapy versuseplerenone in chronic central serous chorioretinopathy(SPECTRA): A randomized controlledtrial. Am J Ophthalmol 2022;233:101–10.

5. Barrientos OR, González MAL. Coriorretinopatíaserosa central crónica. En época depandemia por covid-19. Serie de casos. RECIMUNDO2020;4(4):216–27.

6. Schworm B, Siedlecki J, Keidel LF, HeroldTR, Luft N, Priglinger SG. Subthreshold lasertherapy with a standardized maculartreatment pattern in chronic central serouschorioretinopathy. Graefe’s Arch Clin Exp2021;259(11):3271–81.

7. Choudhary S, Goyal N, Gupta V. Bilateralcentral serous chorioretinopathy post steroidtherapy for facial nerve palsy in a 58-yearoldfemale. Neurology India 2021;69(6):1888

8. Aravind H, Rajendran A, Baskaran P, LoboS, Vempati J, Anthony E. Acute central serouschorioretinopathy following subconjunctivaltriamcinolone acetonide injection in cataractsurgery (less drop approach) - A caseseries. Indian J Ophthalmol2022;70(3):1066–1668.

9. Kim YH, Kang E, Oh J. Factors related to thelocation of pigment epithelial detachment incentral serous chorioretinopathy. Sci Rep2022;12(1):4507-4515.

10. Ko J, Han J, Yoon J, Park JI, Hwang JS, HanJM, et al. Assessing central serous chorioretinopathywith deep learning and multiple opticalcoherence tomography images. Sci Rep2022;12(1):1831-1838.

11. Herold TR, Prause K, Wolf A, Mayer WJ, UlbigMW. Spironolactone in the treatment ofcentral serous chorioretinopathy - a case series.Graefes Arch Clin Exp2014;252(12):1985–1991.

12. Salehi M, Wenick AS, Law HA, Evans JR,Gehlbach P. Interventions for central serouschorioretinopathy: a network meta-analysis.Cochrane Library 2015;2015(12): 1-137.

13. Han JY, Kim YJ, Choi EY, Lee J, Lee JH,Kim M, et al. Therapeutic efficacy of spironolactonefor central serous chorioretinopathy.Yonsei Med J 2022;63(4):365–371.